DRKS00021732招募中未知
Treatment of Sars-CoV2 infections (Covid-19) with valsartan vs placebo, a three-armed randomized, partly blinded trial - CovidVal01
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients aged over 18 years with given consent, first positive Sars-Cov2 detection within the last three days
- •- Patients with pre-existing chronic renal insufficiency in any degree of severity
- •- Patients of both gender
排除标准
- •- intolerance to RAS-I and ARB
- •- Contraindications against ACE/ARB according to current clinical standard
- •- History of falls (more than 2 falls in the last 8 weeks)
- •- Symptomatic hypotension (i.e. blood pressure < 100 mmHg systolic and/or 50 mmHg diastolic together with hypotensive symptoms)
- •- Acute renal failure from stage 2
- •- pregnancy
研究者
相似试验
尚未招募
不适用
se of Hemopurifier Device For The Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans.CTRI/2021/10/037591Aethlon Medical Inc
进行中（未招募）
1 期
Is there a benefit in treating novel corona virus (Sars-CoV2) infections with the established antihypertensive valsartan?Sars-Cov2 infectionEUCTR2020-001431-27-DEKlinikum St. Georg gGmbH300
进行中（未招募）
1 期
Hydroxychloroquine as a treatment for coronavirus disease COVID-19EUCTR2020-000890-25-FRFondation Méditerranée Infection (FMI) - IHU Méditerranée Infection25
招募中
不适用
Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumabsevere SARS-CoV-2 pneumoniaCOVID-19SARS-CoV-2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusSevere Acute Respiratory SyndromeRPCEC00000311Center of Molecular Immunology (CIM)80
尚未招募
不适用
Will treatment with a drug named colchicine be useful in treating Corona virus infection in kidney failure patients who are on regular dialysis?CTRI/2021/05/033537CMC Fluid research Funding